Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical details of transplant recipients

From: Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients

  Case 1 Case 2 Case 3
Primary organ pathology Alcoholic liver disease Tubulo-interstitial nephritis with focal sclerosis End stage renal failure of unknown aetiology (diabetes/hypertension)
Age at transplantation (years) 58 48 57
Ethnicity Caucasian Black Caribbean Indian
Organ transplanted Liver Kidney Kidney
Class 1 HLA type A01, A24, B08, B15, C03, C07
DR1, DR3 DQ2, DQ5
A3, A34, B51, B71, Cw3, Cw16,
DR13, DQ7
A3, A24; B52, B55; Cw1, Cw12;
DR10 DR14; DQ5
Peri-operative immune suppression Basiliximab
Mycophenolate, Tacrolimus
Post operative immune suppression Mycophenolate, tacrolimus None Tacrolimus, prednisolone
Day post transplant antiretrovirals commenced Day 19 Day 17 Day 26
Dose of antiretrovirals Zidovudine 250 mg bd
Raltegravir 400 mg bd
Zidovudine 100 mg tds
Raltegravir 400 mg bd
Zidovudine 100 mg tds
Raltegravir 400 mg bd
Day antiretrovirals stopped Day 66 Day 43 Day 80
Day organ removed Not applicable Day 0 Day 48
Indication for organ removal Not applicable Life-threatening intra-operative haemorrhage Rejection/failure
  1. b.d. Bis in die (twice a day), t.d.s. ter die sumendum (three times daily)